INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP

Summary

To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP.

Timeline

Start

2023-12-11

Primary completion

2026-04-14

Completion

2026-05-19

Outcome

Met primary endpoint

release “demonstrating favorable efficacy in which the primary endpoint was met, and safety from the global phase 3 clinical trial (INSPIRE study) of MT-7117” tanabe-pharma.com ↗

Drugs

Indications